Canadians Face Longer Wait for Copycat Ozempic on Filing Holdup
Canadians face a longer-than-expected wait for cheaper versions of Novo Nordisk A/S's diabetes drug Ozempic after two of the biggest generics makers were hit with additional requests from the health regulator.
(Financial Post, 2025-12-23T17:15:46Z)